關鍵數據
21.700今開
23.000最高
86.44K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
0.13%換手率
21.700昨收
21.095最低
1.92M成交額
虧損本益比靜
5.36市淨率
0.00%股息率 TTM
-30.18%ROA
51.72052週最高
0.03量比
-239.56M淨利潤
69.37M總股本
-3.4918每股盈餘TTM
0.91Beta
-228.24%ROE
8.73052週最低
8.78%振幅
95.46%毛利率
1.58B總市值
3.60回報/風險
8.41%風險率

即將為您帶來更多新聞,敬請期待。 。 。
Uniqure NV評分
0.01與上次評分對比預測8.77
財務診斷5.61
技術分析4.50
公司估值8.35
機構認同度10.00
風險評估3.82
分析師評級
買入評級
59.750目標均價
+140.64%漲幅空間
Uniqure NV 最新財報電話會記錄
uniQure (QURE) 2026 年第三季財報電話會議:AMT-130 優先審查與 2030 年現金可用期
uniQure 2026 年第三季財報電話會議:AMT-130 獲得 FDA 優先審查資格,營收達 520 萬美元,7.684 億美元的現金儲備可支持營運至 2030 年。
財務指標
貨幣: USD

由於公司未披露,未能獲取相關數據
貨幣: USD

由於公司未披露,未能獲取相關數據
Uniqure NV 簡介
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
行業生物技術與醫療研究
公司代碼QURE
員工數量209
國家Netherlands
持股情況
| 持股股東 | 佔比 |
|---|
| Avoro Capital Advisors LLC | 9.75% |
|---|
| Fidelity Management & Research Company LLC | 8.78% |
|---|
| abrdn Inc. | 8.41% |
|---|
| RTW Investments L.P. | 5.88% |
|---|
| 股東類型 | 佔比 |
|---|
| Investment Advisor/Hedge Fund | 41.72% |
|---|
| Investment Advisor | 31.71% |
|---|
| Hedge Fund | 20.62% |
|---|
| Research Firm | 5.66% |
|---|
常見問題
Uniqure NV(QURE)的當前股價是多少?
Uniqure NV(QURE)的當前股價是 22.79。
Uniqure NV股票的52週最高點是51.72。
Uniqure NV股票的52週最低點是8.73。
現在Uniqure NV(QURE)的股票是買入、持有還是賣出?
根據分析師評級,Uniqure NV(QURE)的總體評級為買入,目標價格為59.75。
Uniqure NV(QURE)股票的每股收益(EPS TTM)是多少
Uniqure NV(QURE)股票的每股收益(EPS TTM)是-3.49。